MGX
Metagenomi, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$1.17
+0.86%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.4x
Market Cap
$44.20M
MomentumView details →
1D Return
+0.86%
YTD Return
−28.36%
RSI (14)
37.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.4x
Market Cap
$44.20M
RSI (14)
37.1
MomentumView details →
1D Return
+0.86%
YTD Return
−28.36%
SummaryUpdated Jun 1, 2026
Metagenomi, Inc. (NASDAQ:MGX) is a gene editing biotechnology company founded in 2016 and headquartered in Emeryville, California. The company went public in 2006 and focuses on developing therapeutic treatments using advanced genome editing technologies derived from metagenomics research. Metagenomi has established strategic partnerships with major pharmaceutical companies including Moderna, Affini-T Therapeutics, and Ionis Pharmaceuticals to advance its gene editing platform for various therapeutic applications.
Similar companies
Latest newsMore news →
Metagenomi Therapeutics reported a Q2 2026 loss of $0.73 per share, missing the Zacks Consensus Estimate of a $0.63 loss and wider than the year-ago loss of $0.54 per share.25d agoBrian C. Thomas, Ph.D. resigned as a member of the Board of Metagenomi Therapeutics, Inc., effective June 9, 2026.87d ago